CEO Amber Salzman discusses the benefit of the raise, and contrasts the funding environment in biotech today versus previous years. Plus, she describes the unmet need in FSHD and how AI has already been helping the company understand the patient experience in its current clinical trial.

CEO Amber Salzman walks us through the science, which allows the company to dial up or dial down genes of interest rather than making a cut into the DNA. They have dosed patients with FSHD, a type of muscular dystrophy, and have ASGCT presentations looking at other indications like Friedreich's ataxia, a type of Alzheimer's, and DMD. Coverage brought to you by

She describes why such an analysis would be beneficial in analyzing clinical benefit for this type of condition - where the patient...